The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution Experience.
The Sokal, Hasford, and EUTOS scores were established in different treatment eras of chronic myeloid leukemia (CML). None of them was reported to predict molecular response. In this single center study we tried to reevaluate the usefulness of three main scores in TKI era. The study group included 88 CML patients in first chronic phase treated initially with standard imatinib dose. All of them achieved major molecular response (MMR) in time points defined by European LeukemiaNet (ELN). 42 patients lost MMR in a median time of 47 months and we found a significant difference in MMR maintenance between intermediate-risk (IR) and low-risk (LR) patients assessed by Hasford score. All 42 patients were switched to second-generation TKI (2G-TKI) treatment. At 18 months of 2G-TKI therapy we have still found a significant difference in BCR-ABL transcript levels and MMR rate between IR and LR groups. We did not find any of the described differences discriminating patients by Sokal or EUTOS score. In this retrospective single center analysis we found Hasford score to be useful in predicting molecular response in first chronic phase of CML patients.
Department of Hematology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland; Department of Clinical Genetics, Collegium Medicum of Nicolaus Copernicus University, Bydgoszcz, Poland.
Jarosław
0000-0003-3555-2887
J
Dybko
Department of Hematology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland.
Bożena
B
Jaźwiec
Department of Hematology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland; Department of Clinical Genetics, Collegium Medicum of Nicolaus Copernicus University, Bydgoszcz, Poland.
Olga
O
Haus
Department of Hematology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland; Department of Clinical Genetics, Collegium Medicum of Nicolaus Copernicus University, Bydgoszcz, Poland.
Donata
D
Urbaniak-Kujda
Department of Hematology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland; Department of Clinical Genetics, Collegium Medicum of Nicolaus Copernicus University, Bydgoszcz, Poland.
Katarzyna
K
Kapelko-Słowik
Department of Hematology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland; Department of Clinical Genetics, Collegium Medicum of Nicolaus Copernicus University, Bydgoszcz, Poland.
Tomasz
T
Wróbel
Department of Hematology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland; Jagiellonian University Hospital, Department of Anaesthesiology and Intensive Care, Krakow, Poland.
Tomasz
T
Lonc
Department of Hematology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland; Department of Clinical Genetics, Collegium Medicum of Nicolaus Copernicus University, Bydgoszcz, Poland.
Mateusz
M
Sawicki
Department of Hematology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland; Department of Clinical Genetics, Collegium Medicum of Nicolaus Copernicus University, Bydgoszcz, Poland.
Ewa
E
Mędraś
Department of Hematology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland; Lower Silesian Oncology Center, Department of Radiotherapy, Wroclaw, Poland.
Agnieszka
A
Kaczmar-Dybko
Department of Hematology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland; Department of Clinical Genetics, Collegium Medicum of Nicolaus Copernicus University, Bydgoszcz, Poland.
Kazimierz
K
Kuliczkowski
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D005260:Female; D005500:Follow-Up Studies; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate / Q000627:therapeutic use*; D007124:Immunoenzyme Techniques; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D012720:Severity of Illness Index; D015996:Survival Rate; D055815:Young Adult
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl